Radiodermatitis Market (By Product: Topical, Corticosteroids, Hydrophilic Creams, Antibiotics, Dressings, Hydrogel & Hydrocolloid; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2023-2032

The global radiodermatitis market was estimated at USD 412.66 million in 2022 and it is expected to surpass around USD 604.99 million by 2032, poised to grow at a CAGR of 3.9% from 2023 to 2032.

Radiodermatitis Market Size 2022 to 2032

Key Pointers

  • The topical product segment, with a share of nearly 71.3%, had the biggest market share in 2022. 
  • In 2022, retail pharmacies had the greatest share of the distribution channel segment, accounting for 39.32%.
  • Asia Pacific dominated the market and accounted for 46.07% in 2022.
Report Coverage Details
Market Size in 2022 USD 412.66 million
Revenue Forecast by 2032 USD 604.99 million
Growth rate from 2023 to 2032 CAGR of 3.9%
Base Year 2022
Forecast Period 2023 to 2032
Regions Covered North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Covered Stratpharma AG; Smith & Nephew; Molnlycke Health Care AB; Derma Sciences Inc.; ConvaTec Inc.; BMG Pharma S.R.L.; Acelity; 3M; Alliqua BioMedical

 

The market is predominantly driven by a growing number of patients suffering from radiodermatitis as an adverse effect of radiation therapy. The need for radiodermatitis treatment items is now more urgent than it has ever been because of the need to stop this negative consequence. Radiodermatitis, which includes erythema, dry desquamation, and moist desquamation, affects 95% of cancer patients getting radiation therapy. Also, it is estimated that 85-95% of patients receiving radiotherapy for breastcancer experience radiodermatitis in variable degrees.

As the prevalence of diabetes and obesity increases, the cases of cancer are also rising. According to the Centers for Disease Control, there were 34.2 million cases of diabetes worldwide in 2018; this number is expected to climb to 1.2 billion by 2030. This increase will show that a greater population of patients are more likely to get cancer, and because of a co-morbid condition, they would be more prone to experience radiation-induced skin damage. This is likely to drive the market during the forecast period.

One of the key factors driving this market is the growing number of governmental and private healthcare organisations actively working to raise knowledge about the management and treatment of radiodermatitis. These organisations also publish instructions and suggestions for effectively treating the illness, which is expected to increase the potential for growth throughout the course of the projection period.

For instance, the Provincial Health Services Authority's BC Cancer Agency published information on radiodermatitis risk factors as well as instructions for managing the symptoms of the condition. This is expected to increase knowledge of assessment & treatment methods as well as general skincare advice, boosting potential growth. The product pipeline is expected to grow and the market will have profitable growth opportunities as more clinical studies are conducted to assess the effectiveness of a variety of radiodermatitis treatment products for treatment.

Radiodermatitis Market Segmentations:

By Product

  • Topical
    • Corticosteroids
    • Hydrophilic creams
    • Antibiotics
    • Others
  • Oral
  • Dressings
    • Hydrogel & Hydrocolloid dressings
    • No Sting Barrier Film
    • Honey-Impregnated Gauze
    • Silicone Coated Dressings
    • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online

Frequently Asked Questions

The global radiodermatitis market size was reached at USD 412.66 million in 2022 and it is projected to hit around USD 604.99 million by 2032.

The global radiodermatitis market is growing at a compound annual growth rate (CAGR) of 3.9% from 2023 to 2032.

The Asia Pacific region has accounted for the largest radiodermatitis market share in 2022.

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Radiodermatitis Market 

5.1. COVID-19 Landscape: Radiodermatitis Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Radiodermatitis Market, By Product

8.1. Radiodermatitis Market, by Product, 2023-2032

8.1.1. Topical

8.1.1.1. Market Revenue and Forecast (2019-2032)

8.1.2. Oral

8.1.2.1. Market Revenue and Forecast (2019-2032)

8.1.3. Dressings

8.1.3.1. Market Revenue and Forecast (2019-2032)

Chapter 9. Global Radiodermatitis Market, By Distribution Channel

9.1. Radiodermatitis Market, by Distribution Channel, 2023-2032

9.1.1. Hospital Pharmacies

9.1.1.1. Market Revenue and Forecast (2019-2032)

9.1.2. Retail Pharmacies

9.1.2.1. Market Revenue and Forecast (2019-2032)

9.1.3. Online

9.1.3.1. Market Revenue and Forecast (2019-2032)

Chapter 10. Global Radiodermatitis Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Product (2019-2032)

10.1.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Product (2019-2032)

10.1.3.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Product (2019-2032)

10.1.4.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Product (2019-2032)

10.2.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Product (2019-2032)

10.2.3.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Product (2019-2032)

10.2.4.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Product (2019-2032)

10.2.5.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Product (2019-2032)

10.2.6.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Product (2019-2032)

10.3.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Product (2019-2032)

10.3.3.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Product (2019-2032)

10.3.4.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Product (2019-2032)

10.3.5.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Product (2019-2032)

10.3.6.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Product (2019-2032)

10.4.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Product (2019-2032)

10.4.3.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Product (2019-2032)

10.4.4.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Product (2019-2032)

10.4.5.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Product (2019-2032)

10.4.6.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Product (2019-2032)

10.5.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Product (2019-2032)

10.5.3.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Product (2019-2032)

10.5.4.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)

Chapter 11. Company Profiles

11.1. Stratpharma AG

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Smith & Nephew

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Molnlycke Health Care AB

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Derma Sciences Inc.

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. LTE Scientific

11.5. ConvaTec Inc.

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. BMG Pharma S.R.L.

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Acelity

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. 3M

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Alliqua BioMedical

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers